Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy

Pharmacological Research

Volumn 125, Issue , 2017, Pages 14-20

  Maning, Jennifer ^a   Negussie, Shmuel ^a   Clark, Michelle A ^a   Lymperopoulos, Anastasios ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Adrenal gland; Aldosterone; Angiotensin type 1 receptor; Astrocyte; Heart disease; Arrestin dependent signaling

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ARRESTIN; CANDESARTAN; GUANINE NUCLEOTIDE BINDING PROTEIN; IRBESARTAN; LOSARTAN; VALSARTAN;

ALDOSTERONE RELEASE; ASTROCYTE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CARDIOVASCULAR SYSTEM; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; METABOLISM;

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CARDIOVASCULAR SYSTEM; DRUG AGONISM; DRUG ANTAGONISM; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 85019724261     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.05.009     Document Type: Review

References (66)

1. De Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W., Unger, T., International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000), 415–472.
2. Lefkowitz, R.J., Rajagopal, K., Whalen, E.J., New roles for β-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol. Cell 24 (2006), 643–652.
3. Lefkowitz, R.J., Shenoy, S.K., Transduction of receptor signals by β-arrestins. Science 308 (2005), 512–517.
4. Luttrell, L.M., Gesty-Palmer, D., Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62 (2010), 305–330.
5. Eichel, K., Jullié, D., von Zastrow, M., β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. Nat. Cell Biol. 18 (2016), 303–310.
6. Nuber, S., Zabel, U., Lorenz, K., Nuber, A., Milligan, G., Tobin, A.B., Lohse, M.J., Hoffmann, C., β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature 531 (2016), 661–664.
7. Oakley, R.H., Laporte, S.A., Holt, J.A., Caron, M.G., Barak, L.S., Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275 (2000), 17201–17210.
8. Thomsen, A.R., Plouffe, B., Cahill, T.J. 3rd, Shukla, A.K., Tarrasch, J.T., Dosey, A.M., Kahsai, A.W., Strachan, R.T., Pani, B., Mahoney, J.P., Huang, L., Breton, B., Heydenreich, F.M., Sunahara, R.K., Skiniotis, G., Bouvier, M., Lefkowitz, R.J., GPCR-G protein-β-arrestin super-complex mediates sustained G protein signaling. Cell 166 (2016), 907–919.
9. Weber, K.T., Aldosterone in congestive heart failure. N. Engl. J. Med. 345 (2001), 1689–1697.
10. Connell, J.M., Davies, E., The new biology of aldosterone. J. Endocrinol. 186 (2005), 1–20.
11. Marney, A.M., Brown, N.J., Aldosterone end-organ damage. Clin. Sci. (Lond.) 113 (2007), 267–278.
12. Zhao, W., Ahokas, R.A., Weber, K.T., Sun, Y., ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am. J. Physiol. Heart Circ. Physiol. 291 (2006), H336–H343.
13. Ganguly, A., Davis, J.S., Role of calcium and other mediators in aldosterone secretion from the adrenal glomerulosa cells. Pharmacol. Rev. 46 (1994), 417–447.
14. Rainey, W.E., Saner, K., Schimmer, B.P., Adrenocortical cell lines. Mol. Cell Endocrinol. 228 (2004), 23–38.
15. Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A.D., Koch, W.J., Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13 (2007), 315–323.
16. Lymperopoulos, A., Rengo, G., Koch, W.J., Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol. Med. 13 (2007), 503–511.
17. Lymperopoulos, A., Rengo, G., Zincarelli, C., Soltys, S., Koch, W.J., Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol. Ther. 16 (2008), 302–307.
18. Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S.N., Dorn, G.W., Koch, W.J., Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J. Biol. Chem. 285 (2010), 16378–16386.
19. Lymperopoulos, A., Brill, A., McCrink, K.A., GPCRs of adrenal chromaffin cells & catecholamines: the plot thickens. Int. J. Biochem. Cell Biol. 77 (2016), 213–219.
20. Lymperopoulos, A., Bathgate, A., Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics 13 (2012), 323–341.
21. Jafferjee, M., Reyes Valero, T., Marrero, C., McCrink, K.A., Brill, A., Lymperopoulos, A., GRK2 upregulation creates a positive feedback loop for catecholamine production in chromaffin cells. Mol. Endocrinol. 30 (2016), 372–381.
22. Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D., Filippelli, A., Ferrara, N., Lisanti, M.P., Koch, W.J., Lymperopoulos, A., Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am. J. Physiol. Heart Circ. Physiol. 298 (2010), H2032–H2038.
23. Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D., Pagano, G., de Lucia, C., Cannavo, A., Gargiulo, P., Ferrara, N., Perrone Filardi, P., Koch, W., Leosco, D., Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2)-adrenoceptor-catecholamine production axis in heart failure. Br. J. Pharmacol. 166 (2012), 2430–2440.
24. McCrink, K.A., Brill, A., Lymperopoulos, A., Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failure. World J. Cardiol. 7 (2015), 539–543.
25. Lymperopoulos, A., Rengo, G., Koch, W.J., Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113 (2013), 739–753.
26. Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Soltys, S., Koch, W.J., An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 5825–5830.
27. Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Koch, W.J., Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 57 (2011), 356–365.
28. Nelson, C.D., Perry, S.J., Regier, D.S., Prescott, S.M., Topham, M.K., Lefkowitz, R.J., Targeting of diacylglycerol degradation to M1 muscarinic receptors by b-arrestins. Science 315 (2007), 663–666.
29. Rizzo, M.A., Shome, K., Watkins, S.C., Romero, G., The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J. Biol. Chem. 275 (2000), 23911–23918.
30. Osman, H., Murigande, C., Nadakal, A., Capponi, A.M., Repression of DAX-1 and induction of SF-1 expression. Two mechanisms contributing to the activation of aldosterone biosynthesis in adrenal glomerulosa cells. J. Biol. Chem. 277 (2002), 41259–41267.
31. Liu, C.H., Gong, Z., Liang, Z.L., Liu, Z.X., Yang, F., Sun, Y.J., Ma, M.L., Wang, Y.J., Ji, C.R., Wang, Y.H., Wang, M.J., Cui, F.A., Lin, A., Zheng, W.S., He, D.F., Qu, C.X., Xiao, P., Liu, C.Y., Thomsen, A.R., Cahill, J.T. 3rd, Kahsai, A.W., Yi, F., Xiao, K.H., Xue, T., Zhou, Z., Yu, X., Sun, J.P., Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling. Nat. Commun., 8, 2017, 14335.
32. Sarzani, R., Guerra, F., Mancinelli, L., Buglioni, A., Franchi, E., Dessì-Fulgheri, P., Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am. J. Hypertens. 25 (2012), 818–826.
33. Horita, Y., Taura, K., Taguchi, T., Furusu, A., Kohno, S., Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 11 (2006), 462–466.
34. Bomback, A.S., Klemmer, P.J., The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3 (2007), 486–492.
35. Naruse, M., Tanabe, A., Sato, A., Takagi, S., Tsuchiya, K., Imaki, T., Takano, K., Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40 (2002), 28–33.
36. Lymperopoulos, A., Sturchler, E., Bathgate-Siryk, A., Dabul, S., Garcia, D., Walklett, K., Rengo, G., McDonald, P., Koch, W.J., Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism. J. Am. Coll. Cardiol. 64 (2014), 2805–2806.
37. Dabul, S., Bathgate-Siryk, A., Valero, T.R., Jafferjee, M., Sturchler, E., McDonald, P., Koch, W.J., Lymperopoulos, A., Suppression of adrenal (arrestin1-dependent aldosterone production by ARBs: head-to-head comparison. Sci. Rep., 5, 2015, 8116.
38. Michel, M.C., Foster, C., Brunner, H.R., Liu, L., A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev. 65 (2013), 809–848.
39. Eklind-Cervenka, M., Benson, L., Dahlström, U., Edner, M., Rosenqvist, M., Lund, L.H., Association of candesartan vs losartan with all-cause mortality in patients with heart failure. J. Am. Med. Assoc. 305 (2011), 175–182.
40. Svanström, H., Pasternak, B., Hviid, A., Association of treatment with losartan vs candesartan and mortality among patients with heart failure. J. Am. Med. Assoc. 307 (2012), 1506–1512.
41. Shah, R.V., Desai, A.S., Givertz, M.M., The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J. Card. Fail. 16 (2010), 260–267.
42. Massie, B.M., Carson, P.E., McMurray, J.J., Komajda, M., McKelvie, R., Zile, M.R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., Ptaszynska, A., I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359 (2008), 2456–2467.
43. McKelvie, R.S., Yusuf, S., Pericak, D., Avezum, A., Burns, R.J., Probstfield, J., Tsuyuki, R.T., White, M., Rouleau, J., Latini, R., Maggioni, A., Young, J., Pogue, J., Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100 (1999), 1056–1064.
44. Zhang, H., Unal, H., Gati, C., Han, G.W., Liu, W., Zatsepin, N.A., James, D., Wang, D., Nelson, G., Weierstall, U., Sawaya, M.R., Xu, Q., Messerschmidt, M., Williams, G.J., Boutet, S., Yefanov, O.M., White, T.A., Wang, C., Ishchenko, A., Tirupula, K.C., Desnoyer, R., Coe, J., Conrad, C.E., Fromme, P., Stevens, R.C., Katritch, V., Karnik, S.S., Cherezov, V., Structure of the angiotensin receptor revealed by serial femtosecond crystallography. Cell 161 (2015), 833–844.
45. Miura, S., Feng, Y.H., Husain, A., Karnik, S.S., Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J. Biol. Chem. 274 (1999), 7103–7110.
46. Nikiforovich, G.V., Zhang, M., Yang, Q., Jagadeesh, G., Chen, H.-C., Hunyady, L., Marshall, G.R., Catt, K.J., Interactions between conserved residues in transmembrane helices 2 and 7 during angiotensin AT1 receptor activation. Chem. Biol. Drug Des. 68 (2006), 239–249.
47. Zimmerman, B., Beautrait, A., Aguila, B., Charles, R., Escher, E., Claing, A., Bouvier, M., Laporte, S.A., Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci. Signal., 5, 2012, ra33.
48. Balakumar, P., Jagadeesh, G., Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. J. Mol. Endocrinol. 53 (2014), R71–R92.
49. Wilkes, B.C., Masaro, L., Schiller, P.W., Carpenter, K.A., Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments. J. Med. Chem. 45 (2002), 4410–4418.
50. Holloway, A.C., Qian, H., Pipolo, L., Ziogas, J., Miura, S., Karnik, S., Southwell, B.R., Lew, M.J., Thomas, W.G., Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 61 (2002), 768–777.
51. Qian, H., Pipolo, L., Thomas, W.G., Association of b-arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization. Mol. Endocrinol. 15 (2001), 1706–1719.
52. Tzakos, A.G., Gerothanassis, I.P., Troganis, A.N., On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?. Curr. Top. Med. Chem. 4 (2004), 431–444.
53. Valero, T.R., Sturchler, E., Jafferjee, M., Rengo, G., Magafa, V., Cordopatis, P., McDonald, P., Koch, W.J., Lymperopoulos, A., Structure-activity relationship study of angiotensin II analogs in terms of β-arrestin-dependent signaling to aldosterone production. Pharmacol. Res. Perspect., 4, 2016, e00226.
54. Gainetdinov, R.R., Premont, R.T., Bohn, L.M., Lefkowitz, R.J., Caron, M.G., Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27 (2004), 107–144.
55. Schmid, C.L., Bohn, M., Physiological and pharmacological implication of beta-arrestin regulation. Pharmacol. Ther. 121 (2009), 285–293.
56. Mascolo, A., Sessa, M., Scavone, C., De Angelis, A., Vitale, C., Berrino, L., Rossi, F., Rosano, G., Capuano, A., New and old roles of the peripheral and brain renin-angiotensin-aldosterone-system (RAAS): focus on cardiovascular and neurological diseases. Int. J. Cardiol. 227 (2017), 734–742.
57. Du, D., Chen, J., Liu, M., Zhu, M., Jing, H., Fang, J., Shen, L., Zhu, D., Yu, J., Wang, J., The effect of angiotensin II and angiotensin-(1–7) in the rostral ventrolateral medulla of rats on stress-induced hypertension. PLoS ONE, 8, 2013, e70976.
58. McKinley, M.J., Albiston, A.L., Allen, A.M., Mathai, M.L., May, C.N., McAllen, R.M., Oldfield, B.J., Mendelsohn, F.A., Chai, S.Y., The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 35 (2003), 901–918.
59. Gowrisankar, Y.V., Clark, M.A., Regulation of angiotensinogen expression by angiotensin II in spontaneously hypertensive rat primary astrocyte cultures. Brain Res. 1643 (2016), 8–51.
60. Klett, C., Nobiling, R., Gierschik, P., Hackenthal, E., Angiotensin, I.I., stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA. J. Biol. Chem. 268 (1993), 25095–25107.
61. O'Callaghan, E.L., Bassi, J.K., Porrello, E.R., Delbridge, L.M., Thomas, W.G., Allen, A.M., Regulation of angiotensinogen by angiotensin II in mouse primary astrocyte cultures. J. Neurochem. 119 (2011), 18–26.
62. Uhal, B.D., Zhang, H., Abdul-Hafez, A., Shu, R., Li, X., Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1. Basic Clin. Pharmacol. Toxicol. 100 (2007), 59–66.
63. Karin, M., The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270 (1995), 16483–16486.
64. 1R adaptor protein βarrestin1 in the ERK1/2 activation of SHR-derived primary astrocytes. FASEB J., 30, 2016, 719.6 (EB 2016 Annual Meeting Abstract).
65. Lymperopoulos, A., Bathgate, A., Arrestins in the cardiovascular system. Prog. Mol. Biol. Transl. Sci. 118 (2013), 297–334.
66. Capote, L.A., Mendez Perez, R., Lymperopoulos, A., GPCR signaling and cardiac function. Eur. J. Pharmacol. 763 (2015), 143–148.